<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_CSBJ1869 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id>
    <journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id>
    <journal-title-group>
      <journal-title>Computational and Structural Biotechnology Journal</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2001-0370</issn>
    <publisher>
      <publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9685347</article-id>
    <article-id pub-id-type="pii">S2001-0370(22)00515-3</article-id>
    <article-id pub-id-type="doi">10.1016/j.csbj.2022.11.021</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Data Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MagMD: Database summarizing the metabolic action of gut microbiota to drugs</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Zhou</surname>
          <given-names>Jiajia</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Ouyang</surname>
          <given-names>Jian</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Gao</surname>
          <given-names>Zihao</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au020">
        <name>
          <surname>Qin</surname>
          <given-names>Haipeng</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au025">
        <name>
          <surname>Jun</surname>
          <given-names>Wu</given-names>
        </name>
        <email>jwu@bio.ecnu.edu.cn</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au030">
        <name>
          <surname>Shi</surname>
          <given-names>Tieliu</given-names>
        </name>
        <email>tlshi@bio.encu.edu.cn</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af010" ref-type="aff">b</xref>
        <xref rid="af015" ref-type="aff">c</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="af005"><label>a</label>Center for Bioinformatics and Computational Biology, and the Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai 200241, China</aff>
      <aff id="af010"><label>b</label>School of Statistics, Key Laboratory of Advanced Theory and Application in Statistics and Data Science-MOE, East China Normal University, Shanghai 200062, China</aff>
      <aff id="af015"><label>c</label>Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University &amp; Capital Medical University, Beijing 100083, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding authors. <email>jwu@bio.ecnu.edu.cn</email><email>tlshi@bio.encu.edu.cn</email></corresp>
      <fn id="fn1">
        <label>1</label>
        <p id="np005">Co-Corresponding authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>20</volume>
    <fpage>6427</fpage>
    <lpage>6430</lpage>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>8</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>8</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 The Authors</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="ab005">
      <sec>
        <p>An increasing number of studies have reported that microbiome can affect drug response by altering pharmacokinetics and pharmacodynamics of formation of toxic metabolites. With the development of metagenomic sequencing, gut microbial composition as well as the metabolic function are drawing more and more attention for the patient stratification. The established microbiota databases provide useful information about the gut microbe-drug interactions. However, these databases generally lacked the detailed effects on substance and the metabolites, which are helpful in elucidating the mechanisms underlying drug biotransformation and personalized medicine. To address these issues, in this study, we developed Metabolic action of gut Microbiota to Drugs (MagMD), a database and a web-service covering 32, 678 records of interactions between 2,146 gut microbes, 36 enzymes and 219 substrates (mainly drugs). The detailed annotations for each entry, including the taxonomic level of microbes, the molecular form and PubChem ID of drugs from PubChem Compound Database, types of microbial secreted enzymes and the original reference links can also be accessed from the web service.</p>
      </sec>
      <sec>
        <title>Availability and implementation</title>
        <p>MagMD is a publicly available resource, constantly updated. It has an intuitive web interface and can be freely accessed at <ext-link ext-link-type="uri" xlink:href="http://www.unimd.org/magmd" id="ir005">http://www.unimd.org/magmd</ext-link>.</p>
      </sec>
    </abstract>
  </article-meta>
</front>
<body>
  <sec id="s0005">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0005">The drug-gut microbiota interactions are bidirectional, and the drug can reduce microbial fitness or alter drug availability through biotransformation. The microbes, in turn, can induce either a positive or a negative effect on drug activity and efficacy <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="bib136" ref-type="bibr">[25]</xref>. The gut microbiota could impact drug activity and efficacy through three main ways, including secreting microbial metabolites to interfere with drug metabolism, producing microbial enzymes to transform drug molecules and modifying drug metabolizing genes or enzymes in host liver or intestinal tissues <xref rid="b0005" ref-type="bibr">[1]</xref>.</p>
    <p id="p0010">So far it has been reported over 180 drugs are regarded as substrates for gut bacterial enzymes, and can be directly transformed by microbes in vivo <xref rid="b0025" ref-type="bibr">[3]</xref>, <xref rid="bib137" ref-type="bibr">[26]</xref>. Gut microbiota can directly metabolize drugs through enzymatic transformation or indirectly affect drugs through some special metabolites or pathways <xref rid="b0035" ref-type="bibr">[4]</xref>. For example, <italic>Eggerthella lenta</italic> secretes cardiac glycoside reductase enzyme to reduce Lactone ring of Digoxin, forming an inactive metabolite (dihydrodigoxin) leading to the bioavailability reduction of Digoxin’s <xref rid="b0040" ref-type="bibr">[5]</xref>, <xref rid="b0045" ref-type="bibr">[6]</xref>. <italic>Clostridium scindens</italic> cleavages the sidechain of Dexamethasone, liberating an androgen metabolite, reducing drug concentration in the caecum, and increasing androgen metabolite concentration in the caecum and serum <xref rid="b0025" ref-type="bibr">[3]</xref>. Enright et al. found that the activity of microbial enzyme affects the solubilisation capacity of bile salts to dissolve nine oral drugs including the antiepileptic phenytoin <xref rid="b0050" ref-type="bibr">[7]</xref>. The microbiome can also change the epithelial permeability <xref rid="b0055" ref-type="bibr">[8]</xref>, gut motility <xref rid="b0060" ref-type="bibr">[9]</xref> and other new mechanisms mediated drug absorption <xref rid="b0065" ref-type="bibr">[10]</xref>, <xref rid="b0070" ref-type="bibr">[11]</xref>. Hence, the mechanistic elucidation of gut microbiota in drug metabolism and toxicity will facilitate the rational drug design and provide important evidence for gut microbiota-target therapeutic.</p>
    <p id="p0015">Considering the importance of gut microbiota-drug interactions, several databases have been designed. PharmacoMicrobiomic contains 131 records about the gut microbiota and drug interactions, yet most of them only describe the effects of drugs on the gut microbiota <xref rid="b0075" ref-type="bibr">[12]</xref>. Sun et al. provided a Microbe-Drug Association Database (MDAD) including 5,055 entries involving 1,388 drugs and 180 microbes from drug databases and related publications <xref rid="b0080" ref-type="bibr">[13]</xref>. Microbiota-Active Substance Interactions database (MASI) provides 3,694 entries about the active substance-microbiota interactions with specific species name, whereas only 7.12% of which have the detailed effects on substance and 11.02% of which have the records of metabolites <xref rid="b0085" ref-type="bibr">[14]</xref>. Since these details are helpful in elucidating the mechanisms underlying drug biotransformation and personalized medicine. A typical example is that co-administration of the antiviral drug solivudine with the antitumor drug 5-fluorouracil (5-FU) can increase circulating 5-FU levels, resulting in 5-FU-related death, as the gut microbiota can transform solivudine into (E)-5-(2-bromovinyl)uracil (BVU) which is an inhibitor of hepatic dihydropyrimidine dehydrogenase and hepatic dihydropyrimidine dehydrogenase is responsible for the detoxification of 5-FU <xref rid="b0090" ref-type="bibr">[15]</xref>, <xref rid="b0095" ref-type="bibr">[16]</xref>. Moreover, gaining the product information of microbial metabolic substrates can aid in drug development. Gut microbiota enzymes, such as β-glucosidase and <italic>endo</italic>-β-glucosidase, can convert quercetin to aglycone, exhibiting antiplatelet activity. Hesperetin and naringenin belong to flavonoids like quercetin, which can also be converted into aglycones by gut microbiota enzymes <xref rid="b0100" ref-type="bibr">[17]</xref>, <xref rid="b0105" ref-type="bibr">[18]</xref>. According to the efficacy of quercetin, we can infer that hesperetin and naringenin may also have antiplatelet activity.</p>
    <p id="p0020">To better address demands mentioned above, in this study, we developed a new and regularly updated database, MagMD, to provide detailed information about 32,695 entries about the metabolic action between 2,146 gut microbes and 219 substrates. The details about the enzymes, metabolites and effects on substrates involved in the metabolic processes were also included. Our MagMD provides a user-friendly interface allowing easy access to the data. This platform provides a quick search of the database via its website at <ext-link ext-link-type="uri" xlink:href="http://www.unimd.org/magmd" id="ir010"><underline>http://www.unimd.org/magmd</underline></ext-link>.</p>
  </sec>
  <sec id="s0010">
    <label>2</label>
    <title>Materials and methods</title>
    <sec id="s0015">
      <label>2.1</label>
      <title>Database sources and preprocessing</title>
      <p id="p0025">To collect the details involved in the drug-gut microbiota interactions, we first collected the publication using the PubMed ID recorded in the publicly available database (e.g. PharmacoMicrobiomic and MASI), and then search the related literatures from the PubMed <xref rid="b0110" ref-type="bibr">[19]</xref> with the keywords “gut microbiota”, “metabolism”, “gut microbiome”, “drug metabolism”, “gut microbiome” and “drug pharmacokinetics”. The literature-reported interaction entries were manually extracted from the collected publications and only the experimentally determined interactions were retained. After that 740 literature-reported records from 113 publications were included in the MagMAD, as well as the experimental details (e.g. Drug category, molecular formula and potential effects to the pharmaceutical efficacy) involved in the drug-gut microbiota interactions reported in the original publications were recorded if available. More details related to the drug metabolism were supplemented by integrating the information obtained from UniprotKB <xref rid="b0115" ref-type="bibr">[20]</xref>, ChemicalBook (<ext-link ext-link-type="uri" xlink:href="https://www.chemicalbook.com/ProductIndex_EN.aspx" id="ir015">https://www.chemicalbook.com/ProductIndex_EN.aspx</ext-link>), PubChem Compound <xref rid="b0120" ref-type="bibr">[21]</xref> and Drugbank <xref rid="b0125" ref-type="bibr">[22]</xref>. The potential effects to the pharmaceutical efficacy were further manually evaluated and grouped into 15 classes, such as toxicity increased, toxicity decreased, side effect, carcinogenic, activation, and activity decreased (more details can be found in the web server).</p>
      <p id="p0030">Moreover, as gut microbiota can affect drugs by secreting enzymes, we can build new interactions between the gut microbiota and drugs with the intermediary enzymes. We hypothesized a microbe can affect a drug if the microbe can secret the enzyme which was proved to metabolize the drug. Based on this hypothesis, we first collected information of the enzyme which can metabolize drugs and then the related protein sequences were retrieved from the UniProtKB database (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/" id="ir020"><underline>https://www.uniprot.org</underline></ext-link>). After that, we aligned the protein sequence of each enzyme against the Non-Redundant Protein Sequence Database (NR database) (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein" id="ir025">https://www.ncbi.nlm.nih.gov/protein</ext-link>) using BLASTP. NR proteins with identity larger than 90% and coverage larger than 60% were regarded as matched. The taxonkit <xref rid="b0130" ref-type="bibr">[23]</xref> was applied to assign the enzyme with microbes which were considered to be capable of secreting the enzyme. Hence, novel interactions between the microbes and the drugs were established using the enzymes as intermediary agent and 31,770 records were supplemented to our database.</p>
      <p id="p0035">To further expand our database, we tended to infer the association between the microbes and drugs with computational approach. With the detailed experimental results of 23 drugs metabolized by the gut microbiota of 20 healthy donors reported in Javadan et al.’s study <xref rid="b0135" ref-type="bibr">[24]</xref>, we retrieved the microbial composition (by relative abundance) of the 20 fecal samples as well as the normalized depletion of the 23 FDA approved drugs. For each drug, the key microbes involved in the drug metabolism were inferred using the stepwise linear regression method. Briefly, microbes with mean of relative abundance less than 5e-3 and variance less than 1e-4 across all the samples were filtered. The remained microbes were acted as variables and normalized depletion of the drugs were regarded as the response of the stepwise linear regression method. Microbes with a <italic>p</italic> value less than 0.05 were regarded as key microbes, and then 178 interactions were obtained.</p>
      <p id="p0040">Totally, 32,695 interactions between the microbes and drugs were established with these strategies. To facilitate users to distinguish predicted items, we included the source of each items in our database with the column named “the ways to obtain records”.</p>
    </sec>
    <sec id="s0020">
      <label>2.2</label>
      <title>Webserver construction</title>
      <p id="p0045">We utilized the Apache HTTP server as a web server, developed by PHP (Version: 7.0.12, <ext-link ext-link-type="uri" xlink:href="https://www.php.net/" id="ir030">https://www.php.net/</ext-link>) programming. Data interaction was implemented by HTML5, JavaScript, jQuery. All data in MagMD are stored and managed in MySQL database (Version: 5.7.17, <ext-link ext-link-type="uri" xlink:href="https://www.mysql.com/" id="ir035">https://www.mysql.com/</ext-link>). Data analyses were mainly carried out by the R (Version 3.6.0, <ext-link ext-link-type="uri" xlink:href="https://www" id="ir040">https://www</ext-link>. <ext-link ext-link-type="uri" xlink:href="http://r-project.org/" id="ir045">r-project.org/</ext-link>) or python (Version 3.7.6, <ext-link ext-link-type="uri" xlink:href="https://www" id="ir050">https://www</ext-link>. <ext-link ext-link-type="uri" xlink:href="http://python.org/" id="ir055">python.org/</ext-link>) script.</p>
    </sec>
  </sec>
  <sec id="s0025">
    <label>3</label>
    <title>Results and conclusion</title>
    <p id="p0050">In the current release, our MagMD database holds over 32,695 records describing the interactions between 2,146 gut microbes and 219 substances (94.06% were drugs), involving 195 types of diseases. These records consist of 747 items derived from public databases and literatures, 31,770 items established using enzymes as intermediary agent, and 178 items predicted using the data in Javadan et al.’s study. To provide more details about the interactions, we also included the information of 36 enzymes related to 97.59% of these interactions. Moreover, to give an intuitive description about the effect of gut microbiota to the drug, we grouped the effects of the metabolic action of gut microbes to drugs into 15 types, such as activation, activity decreased, activity increased, inactivation, toxicity decreased, and toxicity increased, according to the original description in the related publications. More details about our database were shown in <xref rid="f0005" ref-type="fig">Fig. 1</xref>. The results showed that the most frequently presented microbe was <italic>Bacteroides uniformis</italic>, which are clinically important species and important in numerous metabolic activities. Similarly, the most frequently presented substance and enzyme were stevioside and β-glucosidase.<fig id="f0005"><label>Fig. 1</label><caption><p>Summary of the records in the MagMD database. <bold>A:</bold> The top 20 frequently presented species in the database. <bold>B:</bold> The top 20 frequently presented enzymes in the database. <bold>C:</bold> The top 20 frequently presented substance in the database. <bold>D:</bold> The record number of effects that gut microbes on the substance.</p></caption><graphic xlink:href="gr1"/></fig></p>
    <p id="p0055">The MagMD also provided a user-friendly interface allowing easy access to the data and also provides a quick search of the database for details via its website at <ext-link ext-link-type="uri" xlink:href="http://www.unimd.org/magmd" id="ir060"><underline>http://www.unimd.org/magmd</underline></ext-link> (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). The webpage consists of four interfaces, which are Home, Browse, Search, Download and About (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). In the Search interface, users can search for metabolic actions by typing any one of the types of bacteria, enzyme substrate or effect. The users can also download all the records from the Download interface in xlsx format. The Browse interface gives the brief summary about the database.<fig id="f0010"><label>Fig. 2</label><caption><p>The web service interface. <bold>A:</bold> The main page of MagMD. <bold>B:</bold> The Overall statistics of MagMD database showed in the About page. <bold>C:</bold> The Search page of MagMD. The user can search metabolic actions of gut microbiota to drugs. <bold>D:</bold> The output page gives a list of metabolic actions related to the keywords entered.</p></caption><graphic xlink:href="gr2"/></fig></p>
    <p id="p0060">Although, there are several databases related to gut microbiota and drugs <xref rid="b0075" ref-type="bibr">[12]</xref>, <xref rid="b0085" ref-type="bibr">[14]</xref> it still necessary to develop a more comprehensive database including the gut microbiota alteration of active substances, along with information on enzymes and effects of drug efficacy after metabolizing by gut microbiota. We believe that the proposed MagMD database will provide a broader knowledge for interaction between gut microbiota and pharmaceutical and better serve the related communities for both basic research and clinical application, such as personalized evaluation of therapeutic efficacy with the gut microbial composition. We also realize clearly some shortcomings of MagMD. As most of the interactions recorded were predicted and the confidence should be further evaluated. Besides that, more details about the interactions are required and the amount of data is not large enough.</p>
  </sec>
  <sec id="s0030">
    <title>Funding</title>
    <p id="p0065">This work was supported by National Natural Science Foundation of China grants (Nos. 31801118, 31671377), Shanghai Municipal Science and Technology Major Project (Grant No. 017SHZDZX01, 20692191500), Beihang University &amp; Capital Medical University Plan (BHME-201904) and the Open Research Fund of Key Laboratory of Advanced Theory and Application in Statistics and Data Science-MOE, ECNU.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of Competing Interest</title>
    <p id="p0070">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>The influence of gut microbiota on drug metabolism and toxicity</article-title>
        <source>Expert Opin Drug Metab Toxicol</source>
        <volume>12</volume>
        <issue>1</issue>
        <year>2016</year>
        <fpage>31</fpage>
        <lpage>40</lpage>
        <pub-id pub-id-type="pmid">26569070</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Falony</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Population-level analysis of gut microbiome variation</article-title>
        <source>Science</source>
        <volume>352</volume>
        <issue>6285</issue>
        <year>2016</year>
        <fpage>560</fpage>
        <lpage>564</lpage>
        <pub-id pub-id-type="pmid">27126039</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>3</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Zimmermann</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mapping human microbiome drug metabolism by gut bacteria and their genes</article-title>
        <source>Nature</source>
        <volume>570</volume>
        <issue>7762</issue>
        <year>2019</year>
        <fpage>462</fpage>
        <lpage>467</lpage>
        <pub-id pub-id-type="pmid">31158845</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>4</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>McCoubrey</surname>
            <given-names>L.E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Predicting drug-microbiome interactions with machine learning</article-title>
        <source>Biotechnol Adv</source>
        <volume>54</volume>
        <year>2022</year>
        <object-id pub-id-type="publisher-id">107797</object-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>5</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>Haiser</surname>
            <given-names>H.J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta</article-title>
        <source>Science</source>
        <volume>341</volume>
        <issue>6143</issue>
        <year>2013</year>
        <fpage>295</fpage>
        <lpage>298</lpage>
        <pub-id pub-id-type="pmid">23869020</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>6</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>Haiser</surname>
            <given-names>H.J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics</article-title>
        <source>Gut Microbes</source>
        <volume>5</volume>
        <issue>2</issue>
        <year>2014</year>
        <fpage>233</fpage>
        <lpage>238</lpage>
        <pub-id pub-id-type="pmid">24637603</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>7</label>
      <element-citation publication-type="journal" id="h0050">
        <person-group person-group-type="author">
          <name>
            <surname>Enright</surname>
            <given-names>E.F.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Impact of Gut Microbiota-Mediated Bile Acid Metabolism on the Solubilization Capacity of Bile Salt Micelles and Drug Solubility</article-title>
        <source>Mol Pharm</source>
        <volume>14</volume>
        <issue>4</issue>
        <year>2017</year>
        <fpage>1251</fpage>
        <lpage>1263</lpage>
        <pub-id pub-id-type="pmid">28186768</pub-id>
      </element-citation>
    </ref>
    <ref id="b0055">
      <label>8</label>
      <element-citation publication-type="journal" id="h0055">
        <person-group person-group-type="author">
          <name>
            <surname>Takashima</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice</article-title>
        <source>Neurogastroenterol Motil</source>
        <volume>32</volume>
        <issue>7</issue>
        <year>2020</year>
        <fpage>e13841</fpage>
        <pub-id pub-id-type="pmid">32319196</pub-id>
      </element-citation>
    </ref>
    <ref id="b0060">
      <label>9</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>González-Sarrías</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP)</article-title>
        <source>J Agric Food Chem</source>
        <volume>61</volume>
        <issue>18</issue>
        <year>2013</year>
        <fpage>4352</fpage>
        <lpage>4359</lpage>
        <pub-id pub-id-type="pmid">23586460</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>10</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Intestinal lysozyme releases Nod2 ligand(s) to promote the intestinal mucosal adjuvant activity of cholera toxin</article-title>
        <source>Sci China Life Sci</source>
        <volume>64</volume>
        <issue>10</issue>
        <year>2021</year>
        <fpage>1720</fpage>
        <lpage>1731</lpage>
        <pub-id pub-id-type="pmid">33521852</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>11</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Ding</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Potential role of Lactobacillus plantarum in colitis induced by dextran sulfate sodium through altering gut microbiota and host metabolism in murine model</article-title>
        <source>Sci China Life Sci</source>
        <volume>64</volume>
        <issue>11</issue>
        <year>2021</year>
        <fpage>1906</fpage>
        <lpage>1916</lpage>
        <pub-id pub-id-type="pmid">33587264</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>12</label>
      <element-citation publication-type="journal" id="h0075">
        <person-group person-group-type="author">
          <name>
            <surname>ElRakaiby</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics</article-title>
        <source>OMICS</source>
        <volume>18</volume>
        <issue>7</issue>
        <year>2014</year>
        <fpage>402</fpage>
        <lpage>414</lpage>
        <pub-id pub-id-type="pmid">24785449</pub-id>
      </element-citation>
    </ref>
    <ref id="b0080">
      <label>13</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Y.Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MDAD: A special resource for microbe-drug associations</article-title>
        <source>Front Cell Infect Microbiol</source>
        <volume>8</volume>
        <year>2018</year>
        <fpage>424</fpage>
        <pub-id pub-id-type="pmid">30581775</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>14</label>
      <element-citation publication-type="journal" id="h0085">
        <person-group person-group-type="author">
          <name>
            <surname>Zeng</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MASI: microbiota-active substance interactions database</article-title>
        <source>Nucleic Acids Res</source>
        <volume>49</volume>
        <issue>D1</issue>
        <year>2021</year>
        <fpage>D776</fpage>
        <lpage>D782</lpage>
        <pub-id pub-id-type="pmid">33125077</pub-id>
      </element-citation>
    </ref>
    <ref id="b0090">
      <label>15</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Nakayama</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil</article-title>
        <source>Pharmacogenetics</source>
        <volume>7</volume>
        <issue>1</issue>
        <year>1997</year>
        <fpage>35</fpage>
        <lpage>43</lpage>
        <pub-id pub-id-type="pmid">9110360</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>16</label>
      <element-citation publication-type="journal" id="h0095">
        <person-group person-group-type="author">
          <name>
            <surname>Okuda</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs</article-title>
        <source>Drug Metab Dispos</source>
        <volume>25</volume>
        <issue>2</issue>
        <year>1997</year>
        <fpage>270</fpage>
        <lpage>273</lpage>
      </element-citation>
    </ref>
    <ref id="b0100">
      <label>17</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>New insights on bioactivities and biosynthesis of flavonoid glycosides</article-title>
        <source>Trends Food Sci Technol</source>
        <volume>79</volume>
        <year>2018</year>
        <fpage>116</fpage>
        <lpage>124</lpage>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>18</label>
      <element-citation publication-type="journal" id="h0105">
        <person-group person-group-type="author">
          <name>
            <surname>Feng</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs</article-title>
        <source>Theranostics</source>
        <volume>10</volume>
        <issue>24</issue>
        <year>2020</year>
        <fpage>11278</fpage>
        <lpage>11301</lpage>
        <pub-id pub-id-type="pmid">33042283</pub-id>
      </element-citation>
    </ref>
    <ref id="b0110">
      <label>19</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Sayers</surname>
            <given-names>E.W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Database resources of the National Center for Biotechnology Information</article-title>
        <source>Nucleic Acids Res</source>
        <volume>39</volume>
        <issue>Database issue</issue>
        <year>2011</year>
        <fpage>D38</fpage>
        <lpage>D51</lpage>
        <pub-id pub-id-type="pmid">21097890</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>20</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Boutet</surname>
            <given-names>E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>UniProtKB/Swiss-Prot</article-title>
        <source>MethodsMol Biol</source>
        <volume>406</volume>
        <year>2007</year>
        <fpage>89</fpage>
        <lpage>112</lpage>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>21</label>
      <element-citation publication-type="journal" id="h0120">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PubChem Substance and Compound databases</article-title>
        <source>Nucleic Acids Res</source>
        <volume>44</volume>
        <issue>D1</issue>
        <year>2016</year>
        <fpage>D1202</fpage>
        <lpage>D1213</lpage>
        <pub-id pub-id-type="pmid">26400175</pub-id>
      </element-citation>
    </ref>
    <ref id="b0125">
      <label>22</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>D.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>
        <source>Nucleic Acids Res</source>
        <volume>46</volume>
        <issue>D1</issue>
        <year>2018</year>
        <fpage>D1074</fpage>
        <lpage>D1082</lpage>
        <pub-id pub-id-type="pmid">29126136</pub-id>
      </element-citation>
    </ref>
    <ref id="b0130">
      <label>23</label>
      <element-citation publication-type="journal" id="h0130">
        <person-group person-group-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>TaxonKit: A practical and efficient NCBI taxonomy toolkit</article-title>
        <source>J Genet Genomics</source>
        <volume>48</volume>
        <issue>9</issue>
        <year>2021</year>
        <fpage>844</fpage>
        <lpage>850</lpage>
        <pub-id pub-id-type="pmid">34001434</pub-id>
      </element-citation>
    </ref>
    <ref id="b0135">
      <label>24</label>
      <element-citation publication-type="journal" id="h0135">
        <person-group person-group-type="author">
          <name>
            <surname>Javdan</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Personalized mapping of drug metabolism by the human gut microbiome</article-title>
        <source>Cell</source>
        <volume>181</volume>
        <issue>7</issue>
        <year>2020</year>
        <fpage>1661</fpage>
        <lpage>1679.e22</lpage>
        <pub-id pub-id-type="pmid">32526207</pub-id>
      </element-citation>
    </ref>
    <ref id="bib136">
      <label>25</label>
      <element-citation publication-type="journal" id="optox9QbrURG6">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Microbiome technology empowers the development of traditional Chinese medicine</article-title>
        <source>Sci China Life Sci</source>
        <volume>63</volume>
        <issue>11</issue>
        <year>2020</year>
        <fpage>1759</fpage>
        <lpage>1761</lpage>
        <pub-id pub-id-type="pmid">32789726</pub-id>
      </element-citation>
    </ref>
    <ref id="bib137">
      <label>26</label>
      <element-citation publication-type="journal" id="optRZAVmFQQ03">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A cyclin protein governs the infectious and sexual life cycles of Cryptococcus neoformans</article-title>
        <source>Sci China Life Sci</source>
        <volume>64</volume>
        <issue>8</issue>
        <year>2021</year>
        <fpage>1336</fpage>
        <lpage>1345</lpage>
        <pub-id pub-id-type="pmid">33165808</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <ack id="ak005">
    <title>Acknowledgements</title>
    <p id="p0075">We thank ElRakaiby et al., Zeng et al and Javdan et al. for their wonderful research results.</p>
  </ack>
</back>
